Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy
characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective …

Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy
caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute …

Abstract Background In December 2020 the Israeli Health Ministry began a mass
vaccination campaign with the BNT162b2 vaccine. This was an important step in …

Abstract Background The von Willebrand factor–directed nanobody caplacizumab has
greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in …

Twenty‐five years ago, intravenous thrombolysis has revolutionized the care of patients with
acute ischemic stroke. Since 2015, randomized clinical trials have demonstrated that …

The 100th anniversary of the first description of Thrombotic Thrombocytopenic Purpura
(TTP) as a disease by Dr. Eli Moschcowitz approaches. For many decades, TTP remained …

Abstract von Willebrand factor (VWF) and factor VIII (FVIII) circulate in a noncovalent
complex in blood and promote primary hemostasis and clotting, respectively. A new VWF A1 …

Background Thrombus formation involves coagulation proteins and platelets. The latter,
referred to as platelet‐mediated thrombogenesis, is predominant in arterial circulation …